南京化纖(600889.SH)2020年業績扭虧 預盈1000萬元-2400萬元
格隆匯1月22日丨南京化纖(600889.SH)披露2020年年度業績預盈公吿,預計2020年年度實現歸屬於上市公司股東的淨利潤為1000萬元到2400萬元,實現扭虧為盈;扣除非經常性損益事項後,預計公司2020年年度歸屬於上市公司股東的淨利潤為-2.10億元到-2.35億元。
業績扭虧主要原因系:(1)公司下屬全資子公司金羚生物基於2020年度收到地方政府下撥的資產損失補助資金及專項獎補資金。(2)金羚生物基通過公開掛牌方式轉讓了其所持的南京法伯耳污水處理有限公司100%股權,產生淨收益。(3)公司利用閒置資金購買保本理財產品獲得理財收益。(4)公司通過公開掛牌方式處置了閒置的粘膠長絲生產線等相關固定資產也形成了部分收益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.